American Century Companies Inc. Decreases Stock Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

American Century Companies Inc. decreased its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 52.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,038,610 shares of the company’s stock after selling 2,247,295 shares during the period. American Century Companies Inc.’s holdings in GoodRx were worth $9,480,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in GDRX. Gagnon Securities LLC grew its stake in GoodRx by 9.9% during the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company’s stock valued at $325,000 after purchasing an additional 6,266 shares in the last quarter. Swiss National Bank boosted its stake in shares of GoodRx by 4.1% during the 4th quarter. Swiss National Bank now owns 161,400 shares of the company’s stock valued at $751,000 after buying an additional 6,400 shares during the last quarter. Fortem Financial Group LLC grew its position in shares of GoodRx by 7.2% during the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock worth $554,000 after buying an additional 7,996 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in shares of GoodRx in the third quarter worth $73,000. Finally, Versor Investments LP acquired a new stake in GoodRx in the fourth quarter valued at $54,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $4.57 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a market capitalization of $1.75 billion, a PE ratio of -152.33, a P/E/G ratio of 2.46 and a beta of 1.25. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26. The business’s fifty day moving average price is $4.75 and its two-hundred day moving average price is $5.23.

Wall Street Analyst Weigh In

GDRX has been the subject of several recent analyst reports. KeyCorp decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Morgan Stanley lowered their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Citigroup cut their price objective on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Mizuho initiated coverage on GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target for the company. Finally, Wells Fargo & Company dropped their price target on GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, GoodRx presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.18.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.